Interventional effect evaluation of Granulomatous Lobular Mastitis patients treatment with Danazol

Clinical trial for evaluation of Granulomatous Lobular Mastitis patients treatment with Danazol

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105266606N1

Enrollment

Registered

2011-09-04

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulomatous Lobular Mastitis. Inflammatory disorders of breast

Interventions

Drug treatment with Danazol 100mg daily until cure patients.

Treatment - Drugs

Drug treatment with Danazol 100mg daily until cure patients

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria:All patients with granulomatous lobular mastitis that has not been treated. Exclusion criteria: incidence of side effect of Danazol and/or patient avoidance for study continue

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Breast pain. Timepoint: Before intervention,monthly after intervention. Method of measurement: Visual Analog Scale.	—

Secondary

Measure	Time frame
Duration of breast pain. Timepoint: Before intervention,monthly after intervention. Method of measurement: Patients' medical document.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoozbeh Rahbar

Ahwaz Jondishapur University of Medical Science

roozbeh.rahbar@yahoo.com+98 61 1333 3477

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026